ASAM Weekly for June 20th, 2023
June 22, 2023
June 22, 2023
CHEVY CHASE, Maryland, June 22 (TNSjou) -- The American Society of Addiction Medicine issued the following ASM Weekly roundup:
Not often do we lead with a study of a first-in-class pharmacotherapy, especially one that treats cannabis use disorder. Known as a signaling-specific inhibitor of the cannabinoid receptor type 1 (CB1-SSi), this new drug works by selectively targeting only a subset of intracellular processes resulting in a therapeutic that can reduce the use and subjective e . . .
Not often do we lead with a study of a first-in-class pharmacotherapy, especially one that treats cannabis use disorder. Known as a signaling-specific inhibitor of the cannabinoid receptor type 1 (CB1-SSi), this new drug works by selectively targeting only a subset of intracellular processes resulting in a therapeutic that can reduce the use and subjective e . . .